Miami, FL (PRWEB) February 26, 2012
A newly published study suggests two strategies to prevent or delay the progression of Alzheimer, more specifically, an early antioxidant intervention and improving the functions of the neurotransmitters acetylcholine. While agreeing with the early anti-oxidant intervention, Nutri-Med Logic Corp adds that a competent body of research has shown a direct link between Cholinergic System (Acetylcholine) and inflammation. Accordingly, an early anti-inflammatory diet would offer an added benefit, in early Alzheimer’s.
According to this study, in animal models, the recording (spatial) memory impairment was accompanied by significant decrease in neurotransmitter acetylcholine, as well as a decline in the anti-oxidant defense. Thus, suggesting oxidative damage and acetylcholine dysfunctions in early Alzheimer models.
A fairly recent but notable study by the School of Health Science and Healthcare Administration of University of Atlanta, also proposes that lack of methyl groups (a group of nutrients) together with oxidative stressors appears to be a central initiating factor for vascular abnormalities for most Alzheimer disease. (1)
Studies in the role of oxidative damage and Alzheimer patients dates back to 1980’s. Oxidative damage manifests a redox (reduction-oxidation) imbalance. According to The Department of Internal Medicine of University of Miami, the cellular redox is regulated by three systems, two of which are also regulated by glutathione. (2)
This recent study also implicates a decrease in superoxide dismutase (SOD), and glutathione peroxidase, two anti-oxidant systems that protect the cells from oxidative damage, in early Alzheimer models.
R-Alpha Lipoic, a nutrient and a potent internal anti-oxidant, has conclusively shown its ability to increase the glutathione levels in the human body.
Additionally, according to this recent study, improving cholinergic (acetylcholine) dysfunction is the other proposed target in delaying the onset and the progression of Alzheimer’s.
Pathogenesis of Alzheimer’s disease has been directly associated with a deficiency in the brain neurotransmitter acetylcholine.
In the brain, there is continuous conversion from choline (a nutrient) to acetylcholine and, again, back to choline. Agents (inhibitors) that do not permit reconversion of acetylcholine back to choline have been used for the symptomatic treatment of Alzheimer’s patients.
A growing body of evidence suggests the definitive role for acetylcholine in suppression of cytokine (inflammatory agents) release through a “cholinergic anti-inflammatory pathway”
In the normal physiological processes, the human brain and the nervous system resolve inflammation through Resolvin (resolution-phase interaction products) D, a derivative of DHA omega-3 fatty acids, which can only be attained through diet or dietary supplementation.
Lack of DHA Omega-3 fatty acids increases the need for alternative resolution of inflammation, including but not limited to acetylcholine.
In conclusion, Nutri-Med Logic Corp agrees with this study and the early anti-oxidant intervention in Alzheimer’s. Nutri-Med Logic Corp adds that due to the established link between acetylcholine and inflammation, addition of an early anti-inflammatory diet would as important as the anti-oxidant diet.
Nutri-Med Logic Corp is also a producer of dietary supplements such as a Pharmaceutical Grade R-Alpha Lipoic Acid, a potent anti-oxidant and the dietary supplement of choice for the Diabetics, in Germany for decades;
Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy, a pure and effective dietary source of choline and the recommended dietary supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for decades.
Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.
It must be noted that the studies, sources or statements above and below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.
1. Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):222-41
2. Drugs. 2011 Jul 30;71(11):1385-96